Prognostic value of quantifying apoptosis factor expression in favorable histology Wilms tumors

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 1, 2005, Pages 11-14

  Miller, Michal A ^a   Karacay, Bahn ^a   Breslow, Norman E ^b   Li, Sierra ^b   O'Dorisio, M Sue ^a   Grundy, Paul E ^c   Sandler, Anthony D ^a,d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Apoptosis; Caspase 8; Recurrence; Survivin; Wilms tumor

Indexed keywords

CASPASE 8; FAS ANTIGEN; MESSENGER RNA; PROTEIN BID; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN;

APOPTOSIS; CASE CONTROL STUDY; CELL SURVIVAL; CONTROLLED STUDY; HISTOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; MORBIDITY; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR RECURRENCE;

ANTIGENS, CD95; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; CASPASE 8; CASPASES; GENE EXPRESSION; KIDNEY NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 12944252913     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000149961.71266.27     Document Type: Review

References (29)

1. Corn BW, Goldwein JW, Evans I, et al. Outcomes in low-risk babies treated with half-dose chemotherapy according to the Third National Wilms' Tumor Study. J Clin Oncol. 1992;10:1305-1309.
2. Thomas PR. Wilms' tumor: changing role of radiation therapy. Semin Radiat Oncol. 1997;7:204-211.
3. Green DM, Thomas PR, Shochat S. The treatment of Wilms tumor. Results of the National Wilms Tumor Studies. Hematol Oncol Clin North Am. 1995;9:1267-1274.
4. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol. 2001;19:1926-1934.
5. Pachnis A, Pritchard J, Gaze M, et al. Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor. Med Pediatr Oncol. 1998;31:150-152.
6. Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilms tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1995;13:1851-1859.
7. Breslow NE, Norkool PA, Olshan A, et al. Second malignant neoplasms in survivors of Wilms' tumor: a report from the National Wilms' Tumor Study. J Natl Cancer Inst. 1988;80:592-595.
8. Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 2001;19:3719-3724.
9. Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:898-899.
10. Nathan DG, Orkin SH, Gingsburg D, Look AT, eds. Nathan and Oski's Hematology of Infancy and Childhood, 6th ed. Philadelphia: WB Saunders, 2003:1146-1148.
11. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
12. White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia. 2001;15:1011-1021.
13. Meier M, Finch A, Evan G. Apoptosis in development. Nature. 2000;407:796-801.
14. Ambrosini G, Adid A, Altieri D. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
15. Swana HS, Grossman D, Anthony J, et al. Tumor content of the anti-apoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341:452-453.
16. Lu C-D, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808-1812.
17. Teitz T, Lahti J, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med. 2001;79:428-436.
18. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, et al. Loss of caspase 8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol. 2000;35:608-611.
19. Harada K, Toyooka S, Shivapurkar N, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002;62:5897-5901.
20. Takamizawa S, Scott D, Wen J, et al. The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg. 2001;36:37-42.
21. Friesen C, Herr I, Krammer, et al. Involvement of the CD95 receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574-577.
22. Kaufmann SH, Eranshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49.
23. Fulda S, Sieverts H, Friesen C, et al. The CD 95 system mediated drug-induced apoptosis in neuroblastomas. Cancer Res. 1997;57:3823-3829.
24. Engels IH, Stepczynska A, Stroh C, et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene. 2000;19:4563-4573.
25. Bartton SB, MacFarlane M, Cain K, et al. Minireview: protein complexes activate distinct caspase cascades in the death receptor and stress-induced apoptosis. Exp Cell Res. 2000;256:27-33.
26. Tamm I, Wang Y, Sausville E, et al. IAP-Family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315-5320.
27. Azuhata T, Miller M, Kobayashi G, et al. Neuroblastoma progressing to a more malignant phenotype in culture displays enhanced anti-apoptotic characteristics. Abstract AACR, 2003.
28. Reimer T, Herrnring C, Koczan D, et al. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res. 2000;60:822-828.
29. Song K, Chen Y, Wilmen A, et al. TRAIL is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med. 2000;91:1095-1103.